The company announced positive 2-year clinical trial data showing consistent efficacy, significant treatment burden reduction (78-87%), excellent safety profile with no new adverse events, and advancement toward Phase 3 trials. These results support the therapeutic potential of 4D-150 as a foundational backbone therapy for wet AMD, which is a major market opportunity affecting millions of patients globally.
Articles that tag FDMT but are mainly about other companies.
Company secured substantial non-dilutive financing ($200M credit facility) that extends cash runway into H2 2028, provides strategic flexibility, and supports advancement of lead product 4D-150 through Phase 3 development. The financing demonstrates investor confidence in the company's pipeline and clinical progress.
Advanced 4D-150 to Phase III with completed enrollment in 4FRONT-1 trial and positive interim data from Phase I/II PRISM trial; accelerating development program.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
